Want to see ASH full AI Analyst Report?
Operating Income by Segment
Measures profit from operations for each segment after accounting for operating costs, exposing the true earning power once overhead and fixed costs are included. Identifies which parts of Ashland are genuinely profitable, where margins can be improved, and which segments may need restructuring or additional investment.Large, episodic charges—most conspicuously in mid‑2025 and prior big corporate/unallocated hits—are skewing reported operating income and mask the underlying momentum: Life Sciences is the consistent growth engine with volume-led margin resilience, Personal Care shows clear recovery and margin expansion, while Specialty Additives remains volatile due to lower fixed-cost absorption and Hopewell operational issues. Management’s commentary on pricing improvement, inventory drawdown, cash generation and targeted plant optimizations supports a Q4 margin step-up, but timing of full recovery remains uncertain.
Date | Life Sciences | Personal Care | Speciality Additives | Intermediates | Unallocated & Other |
|---|---|---|---|---|---|
Jun 30, 2026 | $45.00M | $29.00M | $3.00M | $3.00M | -$37.00M |
Mar 31, 2026 | $35.00M | $27.00M | -$7.00M | $4.00M | -$20.00M |
Dec 31, 2025 | $17.00M | $11.00M | -$8.00M | $0.00 | -$26.00M |
Sep 30, 2025 | $39.00M | $26.00M | $5.00M | $2.00M | -$11.00M |
Jun 30, 2025 | -$343.00M | $25.00M | -$345.00M | $4.00M | -$49.00M |
Mar 31, 2025 | $28.00M | $28.00M | $7.00M | -$1.00M | -$11.00M |
Dec 31, 2024 | $14.00M | $11.00M | -$5.00M | $3.00M | -$202.00M |
Sep 30, 2024 | $43.00M | $15.00M | $8.00M | $7.00M | -$41.00M |
Jun 30, 2024 | $43.00M | $31.00M | $10.00M | $6.00M | -$151.00M |
Mar 31, 2024 | $50.00M | $25.00M | -$18.00M | $9.00M | -$45.00M |